Treating hepatitis C in African Americans (Q36758665)

16 August 2017

1 reference

title

Treating hepatitis C in African Americans (English)

1 reference

16 August 2017

1 reference

Lennox J Jeffers

1

1 reference

16 August 2017

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

27

1 reference

16 August 2017

3

1 reference

16 August 2017

313-322

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Hepatitis C in African Americans: summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Chronic hepatitis C in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Hepatitis C infection in African Americans: its natural history and histological progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Differences in treatment outcome for hepatitis C among ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Race/ethnic issues in obesity and obesity-related comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Morbidity of chronic hepatitis C as seen in a tertiary care medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Anemia in the Treatment of Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Mathematical modeling of viral kinetics: a tool to understand and optimize therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Treating HCV with ribavirin analogues and ribavirin-like molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

Interference of hepatitis C virus RNA replication by short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01438.X

10.1111/J.1478-3231.2006.01438.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17355451